Literature DB >> 17804994

Electroconvulsive therapy in patients with multiple sclerosis.

Keith G Rasmussen1, B Mark Keegan.   

Abstract

There are relatively few case reports of electroconvulsive therapy (ECT) in patients with multiple sclerosis. We present 3 such patients, all of whom received safe, effective ECT without evidence of acute neurological deterioration. We conclude that patients with multiple sclerosis being considered for ECT should have a thorough neurological evaluation, and the informed consent process should include discussion of the possibility of neurological deterioration. However, review of the literature and of our 3 cases does reveal that ECT can be used safely, at least in the short term. Long-term outcomes in such patients remain uncertain.

Entities:  

Mesh:

Year:  2007        PMID: 17804994     DOI: 10.1097/YCT.0b013e31806548c6

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  5 in total

1.  Treatment of mood disorders in multiple sclerosis.

Authors:  Luis Pintor Pérez; Roberto Sánchez González; Eva Baillés Lázaro
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

Review 2.  The link between multiple sclerosis and depression.

Authors:  Anthony Feinstein; Sandra Magalhaes; Jean-Francois Richard; Blair Audet; Craig Moore
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

Review 3.  Electroconvulsive Therapy in Multiple Sclerosis.

Authors:  Katie Steen; Puneet Narang; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2015 Jul-Aug

4.  Ketamine Therapy for Treatment-resistant Depression in a Patient with Multiple Sclerosis: A Case Report.

Authors:  Michael M Messer; Irina V Haller
Journal:  Innov Clin Neurosci       Date:  2017-02-01

5.  Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations.

Authors:  Maria Skokou; Evanthia Soubasi; Philippos Gourzis
Journal:  ISRN Neurol       Date:  2012-10-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.